Data / Drug companies / Lenalidomide
Lenalidomide: 19 companies and 114 products in the FDA NDC directory
Lenalidomide is listed in the FDA National Drug Code Directory by 19 companies, with 114 products in commercial distribution. 108 of the products (94.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, and the newest product started marketing on April 10, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 19
- Products
- 114
- Generic (ANDA) products
- 108 (94.7%)
- Application numbers
- 18
- Routes
- Oral
- Brand names
- Revlimid
- openFDA record search
- api.fda.gov
Companies that list lenalidomide
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Accord Healthcare Inc. | 6 | capsule | Generic drugs (ANDA) | April 8, 2026 |
| Alvogen Inc. | 6 | capsule | Generic drugs (ANDA) | March 6, 2023 |
| Amneal Pharmaceuticals NY LLC | 6 | capsule | Generic drugs (ANDA) | February 12, 2025 |
| Apotex Corp. | 6 | capsule | Generic drugs (ANDA) | March 9, 2023 |
| Aurobindo Pharma Limited | 6 | capsule | Generic drugs (ANDA) | March 6, 2023 |
| Biocon Pharma Inc. | 6 | capsule | Generic drugs (ANDA) | March 3, 2025 |
| Camber Pharmaceuticals, Inc. | 6 | capsule | Generic drugs (ANDA) | May 11, 2023 |
| Celgene Corporation | 6 | capsule | New drug applications (NDA) | June 6, 2013 |
| Cipla USA Inc. | 6 | capsule | Generic drugs (ANDA) | March 9, 2023 |
| Devatis, Inc. | 6 | capsule | Generic drugs (ANDA) | January 31, 2026 |
| Dr. Reddy's Laboratories Inc. | 6 | capsule | Generic drugs (ANDA) | September 7, 2022 |
| Exelan Pharmaceuticals Inc. | 6 | capsule | Generic drugs (ANDA) | June 10, 2024 |
| Mylan Pharmaceuticals Inc. | 6 | capsule | Generic drugs (ANDA) | September 6, 2022 |
| Novugen Pharma (USA) LLC | 6 | capsule | Generic drugs (ANDA) | April 10, 2026 |
| Padagis US LLC | 6 | capsule | Generic drugs (ANDA) | January 31, 2026 |
| Sun Pharmaceutical Industries, Inc. | 6 | capsule | Generic drugs (ANDA) | March 12, 2023 |
| Teva Pharmaceuticals, Inc. | 6 | capsule | Generic drugs (ANDA) | March 8, 2023 |
| Zydus Lifesciences Limited | 6 | capsule | Generic drugs (ANDA) | March 7, 2023 |
| Zydus Pharmaceuticals USA Inc. | 6 | capsule | Generic drugs (ANDA) | March 7, 2023 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 114 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 108 | 94.7% |
| New drug applications (NDA) | 6 | 5.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Thalidomide Analog | 114 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.